Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug Approach

Ítems similars

• High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity
  per: Yoojeong Oh, et al.
  Publicat: (2026-02-01)
• Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation
  per: Hanhee Cho, et al.
  Publicat: (2022-03-01)
• Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
  per: Hanhee Cho, et al.
  Publicat: (2022-10-01)
• Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity
  per: Man Kyu Shim, et al.
  Publicat: (2022-10-01)
• Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
  per: Itzik Cooper, et al.
  Publicat: (2021-12-01)